Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NAD wrap-up

This article was originally published in The Tan Sheet

Executive Summary

National Advertising Division of the Council for Better Business Bureaus made four inquiries in 1993 regarding advertising claims for OTC drugs, down from five OTC-related actions in 1992. Three out of the four 1993 cases investigated by NAD stemmed from product efficacy claims. The cases involved McNeil's Tylenol ("The Tan Sheet" May 31, 1993, p. 10), Serendipity Media's Oxygen Cocktail and Oxygen Plus capsules, Livingston Labs' PMS Natural Relief ("The Tan Sheet" Dec. 20, 1993, p. 19) and Ciba's Efidac/24 ("The Tan Sheet" Jan. 17, p. 10)

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts